Cerezyme
E1550578
UNEXPLORED
Cerezyme is a biologic enzyme replacement therapy used to treat patients with Gaucher disease type 1 by supplementing the deficient glucocerebrosidase enzyme.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Cerezyme canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T22717589 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Cerezyme Context triple: [Genzyme, hasProduct, Cerezyme]
-
A.
Genzyme
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
-
B.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
C.
Trikafta
Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
-
D.
Strensiq
Strensiq is a prescription enzyme replacement therapy used to treat patients with perinatal-, infantile- and juvenile-onset hypophosphatasia, a rare genetic bone disorder.
-
E.
Hemlibra
Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Cerezyme Target entity description: Cerezyme is a biologic enzyme replacement therapy used to treat patients with Gaucher disease type 1 by supplementing the deficient glucocerebrosidase enzyme.
-
A.
Genzyme
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
-
B.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
C.
Trikafta
Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
-
D.
Strensiq
Strensiq is a prescription enzyme replacement therapy used to treat patients with perinatal-, infantile- and juvenile-onset hypophosphatasia, a rare genetic bone disorder.
-
E.
Hemlibra
Hemlibra is a monoclonal antibody medication used to prevent or reduce bleeding episodes in people with hemophilia A, including those with factor VIII inhibitors.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.